News 2022-08-23
Porton Reports Strong Interim Results 2022
The year 2022 is an important milestone for Porton. Despite of the uncertainties of the external environment, we always keep in mind Porton’s mission of "Enabling public’s early access to good medicines" to overcome those challenges and ensure delivery through an agile and stable management system. In the future, we will maintain keen insights and be more proactive in embracing changes so as to empower our business and help good medicines become accessible to the public earlier.



Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.

News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.